视网膜静脉阻塞继发黄斑水肿的玻璃体内药物注射治疗方案研究进展  

Research progress on intravitreal drug injection therapy for macular edema secondary to retinal vein obstruction

作　　者：孔帆 师燕芸 KONG Fan;SHI Yanyun(The First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi Province,China)

机构地区：[1]山西医科大学第一临床医学院,山西省太原市030001

出　　处：《眼科新进展》2024年第11期920-924,共5页Recent Advances in Ophthalmology

摘　　要：视网膜静脉阻塞(RVO)继发黄斑水肿(ME)及由此引起的眼底解剖结构的损伤是导致视力严重受损的主要原因之一,目前RVO继发ME的治疗以控制黄斑水肿、改善患者视功能为主要目的,玻璃体内注射抗血管内皮生长因子药物或皮质类固醇药物治疗是目前的一线治疗手段,近年来临床上很多研究采取了不同的单一或联合药物治疗方案,比较患者术后及随访的视功能恢复情况,为临床医生提供不同治疗方案的选择依据。本文就RVO继发ME玻璃体内药物注射治疗方案的研究进展作一简要综述。Macular edema(ME)secondary to retinal vein obstruction(RVO)and consequent fundus anatomical structure injury is one of the main causes of severe visual impairment.Currently,the treatment of RVO-ME is mainly aimed at controlling ME and improving visual function,and intravitreal injection of anti-vascular endothelial growth factor drugs or corticosteroid drugs is the first-line treatment method.In recent years,many clinal studies have adopted different single or combination drug treatment regimens to compare the visual function recovery of patients after surgery and during the follow-up,providing clinicians with the basis for selecting different treatment regimens.This article provides a brief review of the research progress of RVO-ME intravitreal drug injection therapy.

关 键 词：视网膜静脉阻塞 黄斑水肿 玻璃体内注射 治疗方案 

分 类 号：R774.1[医药卫生—眼科]